[{"orgOrder":0,"company":"Kinaset Therapeutics","sponsor":"Vectura Ltd","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Vectura Signs Agreement with Kinaset Therapeutics Inc. to Support the Development of VR588 to Treat Asthma","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"November 2020","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase I"},{"orgOrder":0,"company":"Kinaset Therapeutics","sponsor":"Not Applicable","pharmaFlowCategory":"DU","amount":"Not Applicable","upfrontCash":"Not Applicable","newsHeadline":"Kinaset Therapeutics Shares Positive Data from Phase 1b KN-002 Study at ATS 2024","therapeuticArea":"Pulmonary\/Respiratory Diseases","highestDevelopmentStatus":"Phase I","country":"U.S.A","productType":"Small molecule","productStatus":"New Molecular Entity","date":"May 2024","url1":"","url2":"","graph1":"Pulmonary\/Respiratory Diseases","graph2":"Phase I"}]
Find Clinical Drug Pipeline Developments & Deals by Kinaset Therapeutics
KN-002 is a pan-JAK inhibitor formulated as a dry powder for delivery via the non-invasive oral inhalation. It is being evaluated in a Phase 1 for mild to severe asthma and those with COPD.
This agreement provides an opportunity for Vectura to realise value from its historical research and investment in VR588, whilst expanding its CDMO development services portfolio by supporting the product's further development with Kinaset.